Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
1998

Effects of Combretastatin A4 Prodrug on Tumor Perfusion and Energy Status

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): DA Beauregard, PE Thelwall, DJ Chaplin, SA Hill, GE Adams, KM Brindle

Primary Institution: University of Cambridge

Hypothesis

Can changes in tumor perfusion caused by the drug be monitored using MRI and MRS techniques?

Conclusion

Combretastatin A4 prodrug caused significant damage to tumor vasculature, leading to reduced perfusion and decreased energy status detectable by MRI and MRS.

Supporting Evidence

  • The drug caused a significant decrease in tumor perfusion rates.
  • Localized 31P-MRS showed a decline in cellular energy status in the tumor after treatment.
  • The pH of the tumor decreased significantly after drug treatment.
  • Regions of low signal intensity in MRI corresponded to necrosis seen in histological sections.

Takeaway

This study looked at how a drug affects blood flow and energy in tumors, showing that the drug can cause damage that can be seen with special imaging techniques.

Methodology

The study used MRI and MRS to monitor tumor perfusion and energy status in a murine tumor model after administering combretastatin A4 prodrug.

Limitations

The study was conducted in a murine model, which may not fully represent human responses.

Participant Demographics

12- to 16-week-old female CBA mice

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication